-
Something wrong with this record ?
Experimental and Established Oximes as Pretreatment before Acute Exposure to Azinphos-Methyl
DE. Lorke, SM. Nurulain, MY. Hasan, K. Kuča, GA. Petroianu
Language English Country Switzerland
Document type Journal Article
NLK
Free Medical Journals
from 2000
Freely Accessible Science Journals
from 2000
PubMed Central
from 2007
Europe PubMed Central
from 2007
ProQuest Central
from 2000-03-01
Open Access Digital Library
from 2000-01-01
Open Access Digital Library
from 2007-01-01
Health & Medicine (ProQuest)
from 2000-03-01
ROAD: Directory of Open Access Scholarly Resources
from 2000
PubMed
33802843
DOI
10.3390/ijms22063072
Knihovny.cz E-resources
- MeSH
- Survival Analysis MeSH
- Azinphosmethyl chemistry toxicity MeSH
- Cholinesterase Inhibitors pharmacology MeSH
- Inhibitory Concentration 50 MeSH
- Molecular Weight MeSH
- Organophosphorus Compounds chemistry toxicity MeSH
- Oximes pharmacology MeSH
- Pesticides chemistry toxicity MeSH
- Rats, Wistar MeSH
- Proportional Hazards Models MeSH
- Risk MeSH
- Animals MeSH
- Check Tag
- Animals MeSH
- Publication type
- Journal Article MeSH
Poisoning with organophosphorus compounds (OPCs) represents an ongoing threat to civilians and rescue personal. We have previously shown that oximes, when administered prophylactically before exposure to the OPC paraoxon, are able to protect from its toxic effects. In the present study, we have assessed to what degree experimental (K-27; K-48; K-53; K-74; K-75) or established oximes (pralidoxime, obidoxime), when given as pretreatment at an equitoxic dosage of 25% of LD01, are able to reduce mortality induced by the OPC azinphos-methyl. Their efficacy was compared with that of pyridostigmine, the only FDA-approved substance for such prophylaxis. Efficacy was quantified in rats by Cox analysis, calculating the relative risk of death (RR), with RR=1 for the reference group given only azinphos-methyl, but no prophylaxis. All tested compounds significantly (p ≤ 0.05) reduced azinphos-methyl-induced mortality. In addition, the efficacy of all tested experimental and established oximes except K-53 was significantly superior to the FDA-approved compound pyridostigmine. Best protection was observed for the oximes K-48 (RR = 0.20), K-27 (RR = 0.23), and obidoxime (RR = 0.21), which were significantly more efficacious than pralidoxime and pyridostigmine. The second-best group of prophylactic compounds consisted of K-74 (RR = 0.26), K-75 (RR = 0.35) and pralidoxime (RR = 0.37), which were significantly more efficacious than pyridostigmine. Pretreatment with K-53 (RR = 0.37) and pyridostigmine (RR = 0.52) was the least efficacious. Our present data, together with previous results on other OPCs, indicate that the experimental oximes K-27 and K-48 are very promising pretreatment compounds. When penetration into the brain is undesirable, obidoxime is the most efficacious prophylactic agent already approved for clinical use.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21019035
- 003
- CZ-PrNML
- 005
- 20210830100610.0
- 007
- ta
- 008
- 210728s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/ijms22063072 $2 doi
- 035 __
- $a (PubMed)33802843
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Lorke, Dietrich E $u Department of Anatomy and Cellular Biology, College of Medicine and Health Sciences, Khalifa University, Abu Dhabi P.O. Box 127788, United Arab Emirates $u Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi P.O. Box 127788, United Arab Emirates
- 245 10
- $a Experimental and Established Oximes as Pretreatment before Acute Exposure to Azinphos-Methyl / $c DE. Lorke, SM. Nurulain, MY. Hasan, K. Kuča, GA. Petroianu
- 520 9_
- $a Poisoning with organophosphorus compounds (OPCs) represents an ongoing threat to civilians and rescue personal. We have previously shown that oximes, when administered prophylactically before exposure to the OPC paraoxon, are able to protect from its toxic effects. In the present study, we have assessed to what degree experimental (K-27; K-48; K-53; K-74; K-75) or established oximes (pralidoxime, obidoxime), when given as pretreatment at an equitoxic dosage of 25% of LD01, are able to reduce mortality induced by the OPC azinphos-methyl. Their efficacy was compared with that of pyridostigmine, the only FDA-approved substance for such prophylaxis. Efficacy was quantified in rats by Cox analysis, calculating the relative risk of death (RR), with RR=1 for the reference group given only azinphos-methyl, but no prophylaxis. All tested compounds significantly (p ≤ 0.05) reduced azinphos-methyl-induced mortality. In addition, the efficacy of all tested experimental and established oximes except K-53 was significantly superior to the FDA-approved compound pyridostigmine. Best protection was observed for the oximes K-48 (RR = 0.20), K-27 (RR = 0.23), and obidoxime (RR = 0.21), which were significantly more efficacious than pralidoxime and pyridostigmine. The second-best group of prophylactic compounds consisted of K-74 (RR = 0.26), K-75 (RR = 0.35) and pralidoxime (RR = 0.37), which were significantly more efficacious than pyridostigmine. Pretreatment with K-53 (RR = 0.37) and pyridostigmine (RR = 0.52) was the least efficacious. Our present data, together with previous results on other OPCs, indicate that the experimental oximes K-27 and K-48 are very promising pretreatment compounds. When penetration into the brain is undesirable, obidoxime is the most efficacious prophylactic agent already approved for clinical use.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a azinfos-methyl $x chemie $x toxicita $7 D001387
- 650 _2
- $a cholinesterasové inhibitory $x farmakologie $7 D002800
- 650 _2
- $a inhibiční koncentrace 50 $7 D020128
- 650 _2
- $a molekulová hmotnost $7 D008970
- 650 _2
- $a organofosforové sloučeniny $x chemie $x toxicita $7 D009943
- 650 _2
- $a oximy $x farmakologie $7 D010091
- 650 _2
- $a pesticidy $x chemie $x toxicita $7 D010575
- 650 _2
- $a proporcionální rizikové modely $7 D016016
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a riziko $7 D012306
- 650 _2
- $a analýza přežití $7 D016019
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Nurulain, Syed M $u Bio Science Department, COMSATS Institute of Information Technology, Bio Sciences Block, CUI, Park Road, Tarlai Kalan, Islamabad 45550, Pakistan
- 700 1_
- $a Hasan, Mohamed Y $u Department of Pharmacology & Therapeutics, College of Medicine and Health Sciences, UAE University, Al Ain P.O. Box 15551, United Arab Emirates
- 700 1_
- $a Kuča, Kamil $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Rokitanského 62/26, 500 03 Hradec Kralove, Czech Republic
- 700 1_
- $a Petroianu, Georg A $u Department of Pharmacology, College of Medicine and Health Sciences, Khalifa University, Abu Dhabi P.O. Box 127788, United Arab Emirates
- 773 0_
- $w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 22, č. 6 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33802843 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830100610 $b ABA008
- 999 __
- $a ok $b bmc $g 1689960 $s 1139481
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 22 $c 6 $e 20210317 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
- LZP __
- $a Pubmed-20210728